Trial
NCT00567229
Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple Myeloma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Multiple Myeloma and Plasma Cell Neoplasm
Intervention
rituximab
Why stopped
Lack of Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-11-20